Groin soreness can come from hip arthritis

Joint soreness may ease after a few steps

Your first steps may be stiff and slow. A low chair, car seat, or bed can make the groin bite.

You may lose motion a little at a time. Shoes become harder to reach, and your stride may get shorter.

An X-ray can show arthritis, but it can't tell how much the hip limits you. The exam and your daily trouble decide what care is reasonable.

Small changes can make daily chores easier

Keep moving, but don't push through a sharp pinch. Try a short walk on level ground and check how the hip feels the next morning.

Use a firm chair and rise slowly with your hands close for support. A physical therapist can change that strength move if it catches in your groin.

A cane may steady you and take some weight off the hip. Ask your doctor which hand to use and whether your medicines are safe together.

Deep bending isn't useful when it causes a sharp catch. A higher chair gives the joint more room when you sit and stand.

Hip replacement alternatives in Scottsdale depend on your daily limits

Surgery may enter the talk when sleep, walks, and basic chores stay hard. It isn't a failure, and waiting isn't always the safer choice.

Prices and visit counts vary, so this page can't give an honest total. Before agreeing, get the total price, expected visits, home exercises, and likely recovery time in writing.

Bring your X-ray and describe the bad days without playing them down. If treatment doesn't help, ask what the next choice would be.

Keep walks manageable and choose a firm seat that isn't low. Licensed clinic staff, called medical providers by QC Kinetix, offer non-surgical regenerative treatments; they create PRP, or platelet-rich plasma, by spinning a blood sample until platelets are concentrated.

Sources

1. The 2019 ACR/Arthritis Foundation guideline makes STRONG recommendations for exercise, weight loss in people with overweight or obesity, self-efficacy and self-management programmes, tai chi, cane use and oral NSAIDs across hand, hip and knee OA - but its strong recommendations for topical NSAIDs and for intra-articular glucocorticoid injection are specific to the KNEE, not the hip.

   Kolasinski SL, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.. Arthritis & Rheumatology, 2020. DOI: 10.1002/art.41142.

2. OARSI 2019 designates arthritis education plus structured land-based exercise as CORE treatments for hip OA, and explicitly states that intra-articular corticosteroids, intra-articular hyaluronic acid and aquatic exercise - Level 1B/2 treatments for KNEE OA - were NOT recommended for individuals with hip or polyarticular OA. Oral and transdermal opioids are strongly not recommended (Level 5).

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.. Osteoarthritis and Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

3. The 2026 Cochrane update of exercise for hip osteoarthritis (18 trials, 1368 participants) found that against attention control or placebo, exercise may have little to no effect on pain (MD -6.31 points on 0-100, 95% CI -12.98 to 0.35, low certainty) and may improve physical function only slightly; against no treatment or usual care it probably reduces pain slightly (MD -7.19, 95% CI -10.70 to -3.68, moderate certainty) but the review states these improvements are unlikely to be clinically meaningful. This is a weaker result than the equivalent knee evidence and it must not be overstated.

   Hall M, et al. — Exercise for osteoarthritis of the hip.. Cochrane Database of Systematic Reviews, 2026. DOI: 10.1002/14651858.CD007912.pub3.

4. A Bayesian network meta-analysis of 11 randomized trials (1353 patients) in hip osteoarthritis found that at 2-4 months and 6 months NO injectable - corticosteroid, hyaluronic acid or platelet-rich plasma - significantly outperformed a saline placebo injection for pain or function. Pooled change from baseline exceeded the minimal clinically important difference in every arm including placebo.

   Gazendam A, et al. — Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of randomised controlled trials.. British Journal of Sports Medicine, 2021. DOI: 10.1136/bjsports-2020-102179.

5. The AAOS evidence-based clinical practice guideline on Management of Osteoarthritis of the Hip states verbatim: STRONG evidence supports intra-articular corticosteroids to improve function and reduce pain in the SHORT TERM; STRONG evidence does NOT support intra-articular hyaluronic acid, because it does not perform better than placebo for function, stiffness and pain; STRONG evidence supports physical therapy for mild to moderate symptoms; STRONG evidence supports NSAIDs for short-term pain and function; and MODERATE evidence does not support glucosamine sulfate.

   American Academy of Orthopaedic Surgeons — Management of Osteoarthritis of the Hip: Evidence-Based Clinical Practice Guideline.. AAOS, 2017.

6. The AAOS 2024 clinical practice guideline summary for management of osteoarthritis of the hip is based on a systematic review of studies in adults 18 and older and contains eight recommendations and nine options; it also explicitly highlights gaps in the literature and areas needing future research.

   Hannon CP, et al. — American Academy of Orthopaedic Surgeons Clinical Practice Guideline Summary: Management of Osteoarthritis of the Hip.. Journal of the American Academy of Orthopaedic Surgeons, 2024. DOI: 10.5435/JAAOS-D-24-00420.

7. A systematic review of five randomized trials of intra-articular PRP for hip OA (43-111 patients each) reported significant pain reduction and functional improvement in every included study with no major adverse events, but methodological quality ranged from low to high risk of bias and PRP preparation methods differed between studies - so this positive summary rests on a small and heterogeneous base and does not override the placebo-controlled network meta-analysis.

   Almutairi AN, Alazzeh MS — Efficacy and Safety of Platelet-Rich Plasma (PRP) Intra-articular Injections in Hip Osteoarthritis: A Systematic Review of Randomized Clinical Trials.. Cureus, 2024. DOI: 10.7759/cureus.72057.

8. FDA states verbatim that regenerative medicine products including stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosomes have NOT been approved 'for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders affecting blood production.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes.. FDA, 2026.

9. The SPACE randomized trial (240 patients with chronic back pain or hip/knee OA pain) found opioids were NOT superior to non-opioid medications for pain-related function over 12 months, pain intensity was significantly BETTER in the non-opioid group, and medication-related adverse symptoms were significantly more common with opioids. The results do not support initiating opioid therapy for hip osteoarthritis pain.

   Krebs EE, et al. — Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.. JAMA, 2018. DOI: 10.1001/jama.2018.0899.

10. A meta-analysis of nine RCTs found duloxetine produced modest-to-moderate improvement over placebo in osteoarthritis or chronic low back pain (Brief Pain Inventory 24-hour average pain WMD -0.67, 95% CI -0.80 to -0.53), at the cost of more treatment-emergent adverse events (RR 1.25) and more discontinuations for adverse events (RR 2.31), with no difference in serious adverse events.

    Weng C, et al. — Efficacy and safety of duloxetine in osteoarthritis or chronic low back pain: a Systematic review and meta-analysis.. Osteoarthritis and Cartilage, 2020. DOI: 10.1016/j.joca.2020.03.001.

11. Pooled analysis of national joint registries (Australia and Finland, 215,676 hip replacements) put 25-year all-cause construct survival at 57.9% (95% CI 57.1-58.7); pooled case series gave 77.6% (95% CI 76.0-79.2). The authors conclude patients and surgeons can expect a hip replacement to last 25 years in around 58% of patients.

    Evans JT, et al. — How long does a hip replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 15 years of follow-up.. The Lancet, 2019. DOI: 10.1016/S0140-6736(18)31665-9.

12. Hip dysplasia is a leading precursor of hip osteoarthritis and is present in 20% to 40% of patients with hip OA; associated femoral deformities occur in more than 50%, so the structural anatomy of a dysplastic hip must be assessed in multiple planes. Acetabular osteotomy is the usual treatment in the pre-arthritic dysplastic hip.

    Gala L, Clohisy JC, Beaule PE — Hip Dysplasia in the Young Adult.. Journal of Bone and Joint Surgery (Am), 2016. DOI: 10.2106/JBJS.O.00109.